<DOC>
	<DOCNO>NCT02454075</DOCNO>
	<brief_summary>This study evaluate whether treatment YF476 safe effective reduce size type II gastric carcinoid tumour , limit abnormal growth gastric ECL cell , patient Zollinger-Ellison syndrome .</brief_summary>
	<brief_title>YF476 Type II Gastric Carcinoids</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Zollinger-Ellison Syndrome</mesh_term>
	<mesh_term>Gastrinoma</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Inclusion criterion : 1 . Men ; postmenopausal woman ; premenopausal woman sterilise tubal ligation , hysterectomy bilateral oophorectomy ; premenopausal woman use one allow method contraception : condom spermicide intrauterine device . 2 . Patients serum gastrin &gt; 250 pg/mL . 3 . Hepatic function : AST ALT ≤2.0 x ULN ; total bilirubin ≤1.0 x ULN . 4 . Renal function : serum creatinine &lt; 1.0 x ULN . 5 . Haematologic function : Hb ≥10.0 g/dL ; WBC ≥3.5 x 10e9 /L ; ANC ≥1.5 x 10e9 /L ; platelet ≥100 x 10e9 /L . 6 . Coagulation parameter : INR PT ≤1.0 x ULN ; PTT ≤1.0 x ULN . 7 . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . 8 . Willingness give fullyinformed , write consent . Exclusion criterion : 1 . Patients 18 year . 2 . Women pregnant , lactate use steroid contraceptive . 3 . Prior gastric resection bypass . 4 . Planned gastrinoma resection study period . 5 . Patients somatostatin analogue , except therapy &gt; 6 month stable worsen carcinoid . 6 . Inability tolerate endoscopy , refusal endoscopy . 7 . Physical finding , ECG ( especially prolong QTc interval &gt; 450 msec ) , laboratory value pretrial screening assessment could interfere objective trial safety subject . 8 . Certain medicine herbal remedy take 7 day visit 2 . 9 . Participation trial IMP within previous 28 day . 10 . Presence drug alcohol abuse . 11 . History baseline finding : type 1 diabetes mellitus ; pancreatitis ( baseline amylase and/or &gt; 2.0 x ULN ) ; hepatitis B , hepatitis C HIV ; malabsorption syndrome inability swallow retain oral medicine ; major surgery &lt; 28 day prior enrolment ; ECOG performance staus &gt; 2 ; another cancer within 3 year except basal carcinoma skin cervical carcinoma insitu . Also , clinically significant uncontrolled major morbidity include limit ; serious cardiac disease ( unstable angina , s/p myocardial infarction &lt; 1 month ) ; respiratory disease ( advanced COPD pulmonary fibrosis ) ; uncontrolled hypertension ; active systemic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>YF476</keyword>
	<keyword>netazepide</keyword>
	<keyword>gastric carcinoid</keyword>
	<keyword>Zollinger-Ellison syndrome</keyword>
</DOC>